RTS,S Malaria Vaccine Phase IIb Trial Antibody Response Data

Antibody response data from a large RTS,S malaria vaccine phase IIb clinical trial involving 735 young children aged 1–4 years. The dataset includes measurements of IgG responses to specific Plasmodium falciparum CSP epitopes, including NANP2 and J1, and their association with clinical malaria risk. It was authored by Alessia Hysa and shared on figshare under a CC-BY-4.0 license.

Use Cases

• Identifying immunological correlates of protection based on IgG responses to CSP epitopes NANP2 and J1.
• Analyzing antibody cross-reactivity patterns between different CSP epitopes mentioned in the description.
• Modeling the association between specific antibody responses and reduced risk of clinical malaria.
• Comparing antibody Fc-mediated functional activities across different response levels.

Strengths

• Includes data from a large clinical trial cohort of 735 children.
• Focuses on specific, named CSP epitopes (NANP2, J1) with statistically significant hazard ratios reported.
• Links antibody responses to concrete clinical outcomes (reduced malaria risk).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small at 79.4 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Post hoc analysis of antibody responses from an RTS,S phase IIb clinical trial.

Freshness

Last updated 2026-05-14 17:56:09; freshness should be verified.